<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142698</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-317</org_study_id>
    <secondary_id>2016-A02065-46</secondary_id>
    <nct_id>NCT03142698</nct_id>
  </id_info>
  <brief_title>Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis</brief_title>
  <acronym>STEA-MRI</acronym>
  <official_title>Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of 4 MRI methods (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to
      the reference method (liver biopsy) in quantification of hepatic steatosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic steatosis is an increasingly frequent pathology, which can lead to severe
      complications (Cirrhosis, Hepatocellular Carcinoma).

      The poor quantification of steatosis by ultrasound or scanning and the invasiveness of the
      reference method (liver biopsy) make MRI a measurement tool of choice.

      Recent techniques such as proton density measurement with several echoes or spectroscopy are
      increasingly used for the measurement of steatosis.

      At the time of the development of therapeutics to reduce fatty liver disease, the use of MRI
      seems an interesting alternative for longitudinal follow-up in these patients.

      Our study aims to ensure the reliability of these different MRI techniques for accurate
      quantification of liver steatosis and to compare them.

        -  Measurement and influence of hepatic fibrosis

        -  Measurement and influence of intrahepatic iron

        -  Influence of intercurrent liver disease

        -  Comparison of the fat measurement of the different hepatic segments

        -  Reproducibility by measurement of inter-observer concordance
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation coefficient - for each quantitative MRI variable studied - with the histological score of hepatic steatosis.</measure>
    <time_frame>at day 1</time_frame>
    <description>Correlation coefficient - for each quantitative MRI variable studied - with the histological score of hepatic steatosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of intrahepatic iron</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of intrahepatic fibrosis</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of fat in different hepatic segments</measure>
    <time_frame>at day 1</time_frame>
    <description>(MRI )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance between observers</measure>
    <time_frame>at day 1</time_frame>
    <description>(for MRI measurements)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatic Steatosis</condition>
  <condition>MRI</condition>
  <condition>Liver Biopsy</condition>
  <condition>Quantification</condition>
  <arm_group>
    <arm_group_label>Hepatic steatosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quantification of hepatic steatosis</intervention_name>
    <description>Quantification of hepatic steatosis (histology, and in MRI)</description>
    <arm_group_label>Hepatic steatosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing hepatic biopsy (trans-parietal or trans-jugular) in the context of
             liver disease

          -  signature of written consent

        Exclusion Criteria:

          -  Contra-indications to MRI

          -  Refusal of protocol

          -  underage patients and protected adults
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louis BOYER</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrnd.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Louis BOYER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatic steatosis</keyword>
  <keyword>MRImaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

